Diamonds and gold may make some hearts flutter on Valentine's Day, but in a University at Buffalo laboratory, silver nanoparticles are being designed to do just the opposite. The nanoparticles are part of a new family of materials being created in the laboratory of SUNY Distinguished Professor and Greatbatch Professor of Advanced Power Sources Esther Takeuchi, PhD, who developed the lithium/silver vanadium oxide battery. The battery was a major factor in bringing implantable cardiac defibrillators (ICDs) into production in the late 1980s. ICDs shock the heart into a normal rhythm when it goes into fibrillation. Twenty years later, with more than 300, 000 of these units being implanted every year, the majority of them are powered by the battery system developed and improved by Takeuchi and her team. For that work she has earned more than 140 patents, believed to be more than any other woman in the United States. Last fall, she was one of four recipients honored in a White House ceremony with the National Medal of Technology and Innovation.
OrbusNeich Announces First Patient Enrolled In Randomized Clinical Trial Of Genous TM Bio-engineered R Stent TM In China
OrbusNeich announced that the first patient has been enrolled in a randomized clinical trial of the Genous Bio-engineered R stent in China. A multicenter, randomized, controlled study, the trial will enroll 180 patients split evenly between the control and test arms at 11 sites countrywide. The primary study objective is to demonstrate the safety and effectiveness of the Genous Bio-engineered R stent compared to the Medtronic Endeavor Sprint stent. The study population will consist of patients ages 18 to 75 with symptoms of angina or myocardial ischemia. The primary endpoints are difference in Major Adverse Cardiac Event (MACE) rates between the two groups at 12 months following implant and 270 day angiographic Late Loss (LL). Secondary endpoints include all-cause and cardiac mortality, myocardial infarction, in-stent thrombosis, MACE rates at 30, 60, 90, 180 and 270 days, as well as clinically driven Target Lesion Revascularization (TLR), Target Vessel Revascularization (TVR) and Target Lesion Failure (TLF) rates at 30, 60, 90, 180, 270 and 360 days.
New Study Uses Adult Stem Cells In Effort To Save Limbs Of Patients With Peripheral Arterial Disease
Grant Medical Center recently completed the nation's first published study of a new procedure that may give hope to millions of patients facing lower limb amputations from peripheral arterial disease (PAD). PAD is a painful circulatory problem in the legs that affects 10 million Americans. If left untreated, it can lead to serious complications such as stroke, amputation and death. The December issue of The Journal of Vascular Surgery has published the results of a clinical trial at Grant documenting the outcomes of nine patients who received a groundbreaking transplant of adult stem cells. The study was designed to see if the stem cells would cause new blood vessels to grow bypassing severely narrowed or clogged arteries. Six of the patients avoided major amputation through restored blood flow that eliminated their constant pain and healed their ulcerations. "We were pleasantly surprised by our results, " said vascular and endovascular surgeon Randall W. Franz, MD, medical director of the Grant Vascular and Vein Center.
Geneva, situated at the heart of Europe, provides a fitting setting for the 10th Annual Spring Meeting of the European Society of Cardiology Council (ESC) on Cardiovascular Nursing and Allied Professionals (CCNAP), 12 - 13 March 2010, with its special theme: "Uniting to Improve Cardiovascular Practice". "Problems in cardiology are universal, but different countries have developed different ways of managing them. The idea of the Spring meeting is to unite nurses and allied health professionals across the globe, enabling them to share best practice with the ultimate hope of raising standards of practice in cardiology, " said Professor Christi Deaton, Chairperson of the ESC Council on Cardiovascular Nursing and Allied Professions. In the true spirit of Geneva, she added, there is a real international flavour to this year's meeting, with the congress offering simultaneous translation from English (the official language of the ESC) to French, German and Italian. "We're hoping this facility will help us reach out to more delegates than ever before, particularly those who may not feel completely comfortable attending meetings entirely in English.
Migraine sufferers are twice as likely to have heart attacks as people without migraine, according to a new study by researchers at Albert Einstein College of Medicine of Yeshiva University. The study, published in the February 10 online issue of Neurology, found that migraine sufferers also face increased risk for stroke and were more likely to have key risk factors for cardiovascular disease, including diabetes, high blood pressure and high cholesterol. "Migraine has been viewed as a painful condition that affects quality of life, but not as a threat to people's overall health, " said lead investigator Richard B. Lipton, M.D., senior author of the study and professor and vice chair in The Saul R. Korey Department of Neurology at Einstein. He also directs the Headache Center at Montefiore Medical Center, the University Hospital and Academic Medical Center for Einstein. Dr. Lipton added, "Our study suggests that migraine is not an isolated disorder and that, when caring for people with migraine, we should also be attentive to detecting and treating their cardiovascular risk factors.
Researchers have teased out the molecular process that can shut down a marauding, often deadly immune response that kills thousands each year who suffer battlefield casualties, heart attacks, strokes, automobile accidents and oxygen deprivation, according to an article published in the January edition of Molecular Immunology. The article provides additional detail about the enormously complex biomechanics of a reaction first observed in the lab by Neel Krishna, Ph.D., and Kenji Cunnion, M.D., while conducting pediatric research at Children's Hospital of The King's Daughters (CHKD) and Eastern Virginia Medical School (EVMS) in Norfolk, Va. "Military medics and ER doctors know that one of the most common killers is an out-of-control immune system that destroys organs after a patient who has suffered a trauma is ostensibly stabilized, " said Krishna, a pediatric virologist at CHKD and assistant professor of microbiology and molecular cell biology at EVMS. The January publication comes almost four years after the two researchers made a serendipitous and unexpected finding when they inserted a shell of a virus that causes childhood diarrhea into a Petri dish primed to measure the response of primordial immune system.
St. Jude Medical, Inc. (NYSE:STJ) announced European CE Mark approval of its USB cellular adaptor for the Merlin@home(TM) transmitter, a system that allows important patient data from an implantable cardiac device to be wirelessly downloaded and securely transmitted via telephone for review by a physician. The new USB adaptor allows patients using a Merlin@home transmitter to transfer data to their physician over the cellular network, in addition to the existing landline service previously available. "The USB cellular adaptor allows patients who frequently travel or relocate to be free of the restrictions of a traditional telephone line, " said Dr. Helen HГёgh Petersen, of Rigshospitalet in Copenhagen, Denmark. "This addition to the remote monitoring system helps to ensure that patients can stay connected with their device follow-up clinic wherever they may live or travel." The USB cellular adaptor is a small device that plugs into new and existing Merlin@home transmitters. The transmitter typically sits on a patient's bedside table and wirelessly communicates with the patient's device during the night.
Leading Expert In Hemodynamics Aims To Use New Emulator Technology To Eliminate Blood Clotting In Cardiovascular Devices
On Jan. 22, Danny Bluestein, PhD, Professor of Bioengineering at the State University of New York (SUNY) Stony Brook, in collaboration with Marvin J. Slepian, M.D., Professor of Medicine (Cardiology) at the University of Arizona, submitted a Phase II Quantum Grant proposal to the National Institute of Biomedical Imaging and Bioengineering (NIBIB). "During Phase I of this project, we developed and tested the Device Thrombogenicity Emulator (DTE), " said Dr. Bluestein. "The DTE measures the potential for blood clotting in cardiovascular devices by mimicking the conditions in the device as extracted from advanced numerical simulations. Conceptually, it is analogous to a wind tunnel used for aeronautic and automotive testing. "The ultimate goal is to eliminate the need for anticoagulation. During Phase II, we plan to use the DTE to identify 'hot spot' trajectories in the flow fields of cardiovascular devices where clots can form. The DTE methodology enables us to tweak the geometry of the device in order to achieve design optimization aimed at minimizing and eliminating these hot spots.
American Heart Association Rapid Access Journal Report: Study Finds Racial Gaps Continue In Heart Disease Awareness
Racial gaps exist in women's heart-health awareness, women's knowledge of heart attack warning signs requires attention and nearly half of women report they would not call 9-1-1 if they were having heart attack symptoms, according to new research published in Circulation: Cardiovascular Quality and Outcomes, a journal of the American Heart Association. Results of the study, commissioned by the American Heart Association, revealed that although 60 percent of white women were aware of heart disease as the leading cause of death for women, less than half of African-American (43 percent), Hispanic (44 percent) and Asian (34 percent) women identified heart disease as the leading cause. In addition, most women lacked knowledge of evidence-based therapies for preventing cardiovascular disease, and half of women ages 25-34 were unaware of heart disease as women's No. 1 killer, demonstrating the need for prevention education to avert death and disability from heart disease. "The American Heart Association just announced its 2020 strategic goal: by 2020, to improve the cardiovascular health of all Americans by 20 percent while reducing deaths from cardiovascular diseases and stroke by 20 percent, " said Lori Mosca, M.
Next month, in the Norwegian town of Rena, 12, 000 elite cross-country skiers will line up for this year's Birkebeiner ski marathon, an annual endurance race which will take them through 54 kilometres of snow-covered countryside to the winter sports resort of Lillehammer. The race has been run almost every year since 1932, and in 1976 almost 150 participants were invited to take part in a long-term study designed to discover the extent of latent heart disease in these elite cross-country skiers. Now, after some 30 years, the results of the follow-up study have been published and suggest that long-distance competition skiers - as well as other endurance athletes - are at an unusually high risk of atrial fibrillation, the most common abnormality of the heart's beating rhythm.(1) Results showed that participants in the study are at a high risk of atrial fibrillation (AF) without known structural heart disease or other known causes (a condition termed "lone" AF). A prevalence of 12.